The Phase 3 trial will be conducted in approximately 50 major cardiac surgery centers in North America. The trial will enroll patients undergoing coronary artery bypass graphs (CABG) and/or mitral valve surgery who are at risk for developing LCOS. The trial will be a double blind, randomized, placebo controlled study seeking to enroll 760 patients. It is expected that enrollment will begin in the third quarter of 2014, and will take approximately 18 months to complete. More details on the specifics of the trial will be released shortly.
Yes it was so implied and interpreted as so by many posters. That is why I cut and pasted comment by "don.baddabing.baddaboom" and others.
I thought you said it would be a bang. But you sold and misunderstood the PR didn't you?
The scientific research report on Geron's product was outstanding, but the stock still tanked. And, they fear dilution also to come up with the money for trials that may be a year or more down the road to just start.
So, reality has set in.
Broad market sell-off due to S&P is over 25% just this year. Read the reports after the market that funds are selling off to lock in their gains. Expect the market to drop another 2-3% the rest of December. We are just too high.
No problem reaching that in 3-5 days.
people were misled by the Press Release and were assuming everything would be taken care of within 3 months and not 28-30 months:
don.baddabing.baddaboom • 2 hours 45 minutes ago Flag
What the F is this latest press release? What happened to "Fast Track"?
In today's announcement, OXBT state the trials "will begin in the third quarter of 2014, and will take approximately 18 months to complete" but in their press release of 21 Oct 2013, they state "With Fast Track status and an agreed study protocol under the Special Protocol Assessment (SPA), we expect we are one trial away from approval,”. Looking up the Fast track approval, it explicitly says "The FDA Fast Track Development Program is a designation of the United States Food and Drug Administration (FDA) that accelerates the approval of investigational new drugs undergoing clinical trials with the goal review time of 60 days."
So which is it? 60 days or 30 months?
I was correct today at $4.05. I hope I am wrong for tomorrow to fall to $3.75.
It is odd the insiders bought almost triple the number of shares at almost double the price 1.5 years ago.
They got real damaged goods in that stock. I think it will sink back down to $4.
I am thinking of buying that if it falls more tomorrow.
Just buy more. If you bought at $4.60, it is cheap now at $3.90. Just load up now. and load up at $3.50 also. Don't worry....be happy. It is Christmas time of the year.
hahahaha...read the message board there for the last two days. They are going beserk!
Yup, there it is.